scholarly journals Non-cigarette tobacco use among women and adverse pregnancy outcomes

2010 ◽  
Vol 89 (4) ◽  
pp. 454-464 ◽  
Author(s):  
Lucinda J. England ◽  
Shin Y. Kim ◽  
Scott L Tomar ◽  
Cecily S Ray ◽  
Prakash C. Gupta ◽  
...  
Keyword(s):  
Tobacco Use ◽  
Pregnancy Outcomes ◽  
Adverse Pregnancy Outcomes ◽  
Cigarette Tobacco ◽  
Adverse Pregnancy

scholarly journals Tobacco Consumption during Pregnancy and Its Adverse Pregnancy Outcomes: A Systematic Review

2021 ◽  
Vol 11 (4) ◽  
pp. 170-181
Author(s):  
Bandana Dobhal ◽  
Karuna . ◽  
Sana Manzoor Ahmed
Keyword(s):  
Tobacco Use ◽  
Pregnancy Outcomes ◽  
Rural Areas ◽  
Maternal Smoking ◽  
Economic Status ◽  
Tobacco Consumption ◽  
Adverse Pregnancy Outcomes ◽  
Maternal Weight ◽  
Eligibility Criteria ◽  
Adverse Pregnancy

Background: Maternal smoking is known to pose risks to both baby and mother affecting aspects from fertility and pregnancy outcome to fetal and child development. Objective: To study the prevalence of maternal smoking globally and its adverse pregnancy outcomes. Materials and methods: Health sciences electronic databases PubMed and Google Scholar were searched for studies published between 2006 to March 2020. Keywords used for the search were (“tobacco”), ("maternal smoking"), ("effects of maternal smoking") and (“globally”). A total of 29 articles were included in the review based on the eligibility criteria. Statistical software SPSS-V.23 was used for the statistical application. Result: A total of 29 studies met the inclusion criteria with a total of 11,34,769 women, age ranged from 12-45 years and above. Maternal smoking was reported by 22.26% women. Those women who reside in rural areas, illiterate, homemaker, from low economic status and whose husband smoke have higher maternal smoking prevalence and its adverse pregnancy outcomes were reported as 23.27% low maternal weight, 62.46% anaemic mother, 8.76% low birth weight, 12.86% preterm birth, 79% low birth length and 15.77% obesity among children. Conclusion: Maternal tobacco use in any form increases risk of ill effects on mother and child health. Tobacco cessation during pregnancy is necessary to reduce morbidity and mortality related to tobacco use. Key words: Maternal smoking, cigarette, smokeless tobacco, prevalence, effects of maternal smoking, Globally.

scholarly journals Investigating N-3 Fatty Acids to prevent Neonatal Tobacco-related outcomeS (INFANTS): study protocol for a double-blind, randomized, placebo-controlled parallel clinical trial of n-3 polyunsaturated fatty acids in pregnant smokers

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Harvey J. Murff ◽  
Robert A. Greevy ◽  
Reesha S. Sanghani ◽  
Katherine E. Hartmann ◽  
Tina V. Hartert ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Smoking Cessation ◽  
Tobacco Use ◽  
Pregnancy Outcomes ◽  
Preterm Labor ◽  
Adverse Pregnancy Outcomes ◽  
Neonatal Outcomes ◽  
Double Blind ◽  
Pregnant Smokers ◽  
Adverse Pregnancy

Abstract Background Tobacco use during pregnancy is the most important modifiable risk factor associated with adverse pregnancy outcomes, increasing the risk of preterm birth, intrauterine growth restriction and sudden infant death syndrome. Fewer than half of pregnant smokers can quit on their own. Identifying safe and effective therapies to prevent tobacco-related adverse pregnancy outcomes and/or increase smoking cessation in pregnant women would have a substantial public health impact. Cigarette smoking is associated with a relative deficiency in circulating n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) levels. A recent analysis found that smokers taking n-3 LCPUFAs during pregnancy had a reduction in preterm labor risk when compared to non-smokers. Studies have shown that supplemental n-3 LCPUFAs may also reduce nicotine cravings and daily cigarette use. Thus, smokers may benefit from supplemental n-3 LCPUFAs by lowering the risk of preterm labor and/or increased smoking cessation. To address important remaining knowledge gaps, we propose the Investigating N-3 Fatty Acids to prevent Neonatal Tobacco related outcomeS (INFANTS). Methods The INFANTS study is a multicenter, randomized, double-blind, placebo-controlled study that will randomize 400 pregnant smokers to either supplemental n-3 LCPUFAs or placebo. Participants will be enrolled between 12 and 24 weeks’ gestation and followed until 6 weeks after delivery. We will recruit from clinical centers throughout Middle Tennessee. We will assess smoking behavior after 12 weeks of supplementation using self-report and validated biomarkers of tobacco exposure. We will measure response to supplementation using biological markers of n-3 LCPUFA status. Our primary endpoint will be preterm labor as reflected by gestational age at delivery. Our secondary endpoint will be change from baseline in cigarettes per day at 12 weeks. Discussion This study tests the hypothesis that smoking-induced n-3 LCPUFA deficiencies contribute to tobacco-related adverse pregnancy outcomes and that supplementation of n-3 LCPUFAs in pregnant smokers may prevent these complications. If our study demonstrates that supplemental n-3 LCPUFAs are effective at reducing the risk of tobacco-related adverse neonatal outcomes and/or reducing tobacco use during pregnancy, our results could have an immediate and major impact on pregnancy care and neonatal outcomes. Trial registration ClinicalTrials.gov NCT04417595. Registered on April 21, 2020

Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-analysis

2020 ◽  
Vol 26 ◽  
Author(s):  
Yang Zhang ◽  
Dandan Li ◽  
Heng Guo ◽  
Weina Wang ◽  
Xingang Li ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Preterm Birth ◽  
Spontaneous Abortion ◽  
Bowel Disease ◽  
Pregnancy Outcomes ◽  
Congenital Malformations ◽  
Meta Analysis ◽  
Adverse Pregnancy Outcomes ◽  
Inflammatory Bowel ◽  
Adverse Pregnancy

Background: Conflicting data exist regarding the influence of thiopurines exposure on adverse pregnancy outcomes in female patients with inflammatory bowel disease (IBD). Objective: The aim of this study was to provide an up-to-date and comprehensive assessment of the safety of thiopurines in pregnant IBD women. Methods: All relevant articles reporting pregnancy outcomes in women with IBD received thiopurines during pregnancy were identified from the databases (PubMed, Embase, Cochrane Library, and ClinicalTrials.gov) with the publication data up to April 2020. Data of included studies were extracted to calculate the relative risk (RR) of multiple pregnancy outcomes: congenital malformations, low birth weight (LBW), preterm birth, small for gestational age (SGA), and spontaneous abortion. The meta-analysis was performed using the random-effects model. Results: Eight studies matched with the inclusion criteria and a total of 1201 pregnant IBD women who used thiopurines and 4189 controls comprised of women with IBD received drugs other than thiopurines during pregnancy were included. Statistical analysis results demonstrated that the risk of preterm birth was significantly increased in the thiopurine-exposed group when compared to IBD controls (RR, 1.34; 95% CI, 1.00-1.79; p=0.049; I 2 =41%), while no statistically significant difference was observed in the incidence of other adverse pregnancy outcomes. Conclusion: Thiopurines’ use in women with IBD during pregnancy is not associated with congenital malformations, LBW, SGA, or spontaneous abortion, but appears to have an association with an increased risk of preterm birth.

The Need for Personalized Risk-Stratified Approaches to Treatment for Gestational Diabetes: A Narrative Review

2021 ◽  
Author(s):  
Shamil D. Cooray ◽  
Jacqueline A. Boyle ◽  
Georgia Soldatos ◽  
Shakila Thangaratinam ◽  
Helena J. Teede
Keyword(s):  
Gestational Diabetes ◽  
Pregnancy Outcomes ◽  
Population Based ◽  
Adverse Pregnancy Outcomes ◽  
Therapeutic Interventions ◽  
Clinical Prediction Model ◽  
Increased Risk ◽  
Adverse Pregnancy ◽  
The Individual ◽  
Personalized Risk

AbstractGestational diabetes mellitus (GDM) is common and is associated with an increased risk of adverse pregnancy outcomes. However, the prevailing one-size-fits-all approach that treats all women with GDM as having equivalent risk needs revision, given the clinical heterogeneity of GDM, the limitations of a population-based approach to risk, and the need to move beyond a glucocentric focus to address other intersecting risk factors. To address these challenges, we propose using a clinical prediction model for adverse pregnancy outcomes to guide risk-stratified approaches to treatment tailored to the individual needs of women with GDM. This will allow preventative and therapeutic interventions to be delivered to those who will maximally benefit, sparing expense, and harm for those at a lower risk.

Sign in / Sign up

Export Citation Format

Share Document